Cipla Q2 Preview FY2026: Steady Revenue Growth Expected; EBITDA May Decline 4% YoY on Higher R&D Spend

India's leading pharmaceutical company Cipla Ltd is set to announce its July-September quarter (Q2FY26) results on Thursday, October 30, 2025. Analysts expect the drug major to deliver steady year-on-year (YoY) growth in both revenue and profit, driven by healthy performance across its domestic, Africa and European markets, though margins may come under pressure due to higher research and development (R&D) expenditure and pricing challenges in the US segment.

Cipla Q2 Preview 2026: Steady Growth Expected Overseas, Margins May Moderate on Higher R&D Spend

According to Kotak Institutional Equities, Cipla's India business is likely to post a 7% YoY growth in Q2FY26, improving from the 4.7% growth recorded in the same quarter last year. The brokerage attributes this uptick to a recovery in domestic formulations and a low base effect impacted by last year's GST-related distortions.

In the US market, Cipla's performance is expected to remain stable but subdued, with pricing pressure in gRevlimid leading to a marginal decline. Kotak projects US revenue at around $220 million, approximately 3% lower sequentially, as growth from Lanreotide and Albuterol remains largely flat quarter-on-quarter.

Meanwhile, the "One Africa" region continues to perform well. Cipla's African operations are expected to record 9% YoY growth, supported by 8% growth in South Africa and a favourable INR-ZAR exchange rate. Sales in Europe and the rest of the world are projected to climb 10% YoY, aided by improving demand trends and new product launches.

Overall Revenue Growth Seen at 5% YoY

Overall, Kotak Institutional Equities expects Cipla's consolidated Q2FY26 revenue to grow around 5% YoY and 6% sequentially, reflecting balanced growth across geographies. The company's strong portfolio mix, continued traction in key brands, and momentum in the chronic and respiratory segments are likely to support topline performance.

Brokerages also believe that Cipla's consistent execution in regulated markets and its One India-One Africa strategy will continue to drive sustainable growth in the coming quarters.

Cipla Q2 Results: Margins Likely to Moderate on Higher R&D and Cost Pressures

Despite a positive growth outlook, profitability metrics are expected to see some moderation this quarter. Kotak Institutional Equities estimates gross margins to contract by 130 basis points (bps) quarter-on-quarter to 67.5%, primarily due to higher R&D investments and a marginal impact from pricing pressure in key US products.

The brokerage further projects Ebitda to decline 4% YoY to Rs 18 billion, with Ebitda margins slipping 230 bps to 24.4%. Analysts note that while short-term pressure on profitability may persist, these R&D expenses are part of Cipla's long-term strategy to strengthen its global pipeline, particularly in respiratory, complex generics, and biosimilars.

Choice Institutional Equities: R&D Spend and New Launches in Focus

Choice Institutional Equities expects Cipla to maintain steady growth momentum in its Africa business, while other regions are likely to expand in the mid-single digits. The brokerage, however, anticipates slight moderation in operating margins due to increased R&D spending, consistent with the company's strategic focus on innovation.

Key factors to watch, according to Choice, include the performance of Cipla's new biosimilar launch in the US and updates on the GLP-1 portfolio-a new growth opportunity area in the global diabetes and obesity treatment segment.

Disclaimer

The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.